Takeda doubles down at California site as it looks to grow rare disease manufacturing base
Japanese drugmaker Takeda is looking to ramp up the efficiency of its rare diseases manufacturing, which includes programs for hemophilia and Von Willebrand disease. It will turn to a California location it’s familiar with to bring its operations into the future.
Takeda will more than double the size of its Thousand Oaks, CA manufacturing site in an upgrade that will use automation, robotics and digitization to reduce the potential for human error, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.